Drug intelligence / Profile preview

RK003

Development stage: Unknown
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes
Administration: Intraperitoneal

Overview

RK003 is a protein-based therapeutic drug candidate developed by RevolKa Ltd. and Sumitomo Pharma Co., Ltd. It is currently in the discovery phase for the treatment of rare diseases. RevolKa utilizes its proprietary aiProtein® technology, an AI-integrated directed protein evolution platform, for the discovery and development of highly functional proteins.

Beyond the preview

Go deeper on RK003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK003.

Explore the full profile